Drug May Boost Women's Sexual Desire
Study Shows Flibanserin Increases Satisfying Encounters for Women With Low Libido
Second Opinion continued...
"You have to remember these women have lost desire over time and for some time. You have to remember these women [with no sexual desire] are very distressed by it. If you go from zero to one, you're pleased as punch, because you were flat-lining before."
Some wonder if developing a pharmaceutical for women’s lagging desire is more about business than pleasure. "We need to address multiple factors that underlie sexual desire," says Gina Ogden, PhD, a sex therapist in Cambridge, Mass., and author of The Return of Desire. Of the development of flibanserin, she says: "I think the focus is more to line the pockets of the pharmaceutical companies than to address the real and multiple factors involved in women's sexual desire." A woman's desire, says Ogden, is influenced by many factors, including her feelings about sex, what sex means to her, and what types of intimacy she prefers.
Boehringer Ingelheim is continuing studies. Recruitment of both premenopausal and postmenopausal women with HSDD for new clinical trials is beginning, Sand says.
He wouldn't comment on a possible timeline of when the drugmaker might ask for FDA approval or when it may be on the market.